Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia
- First Online:
- 164 Downloads
This study investigates the differential gene expression profile of JAK2V617F-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2V617F-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.
KeywordsPolycythemia vera Essential thrombocythemia Gene expression profile RT-PCR Response to hydroxyurea JAK2 Src family kinase (SFK)
- 2.Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 8:8Google Scholar
- 5.Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107(10):4139–4141, Epub 2006 Jan 24PubMedCrossRefGoogle Scholar